The active ingredient Remdesivir is approved for use in Europe, subject to conditions as the first agent for the therapy of Covid-19. The decision, the EU Commission announced on Friday. “Today’s approval of the first drug for the treatment of Covid-19 is an important step forward in the fight against the Virus,” said health Commissioner Stella Kyriakides. The approval was issued in less than a month after the request.
Remdesivir is considered to be one of the few effective drugs for severe cases of the Coronavirus-induced lung disease. It can be shorten according to studies, the hospital stay. The European medicines Agency EMA recommended the marketing authorisation for patients aged twelve years, a pneumonia, and supplemental oxygen must be supplied.
Remdesivir not a panacea, but light
Doctors don’t see Remdesivir as a panacea, but as a beacon of light for Corona-patients. An international study with over 1000 participants has shown at the end of April, that Remdesivir at Covid-19-patients can shorten the time to recovery in an average of four days – from 15 to eleven days.
To the point
Corona-News: A drug that makes hope
The Coronavirus is from the beats to the lung, but other organs can be affected? And a hope called Remdesivir – new studies and findings to Covid-19.
The US had already been issued at the beginning of may a derogation for the limited use of the drug in hospitals. In Germany, too, the Mediterranean was already within a compassionate use program is accessible and has been tested in clinical trials.
The US government had made known this week an agreement with the US manufacturer Gilead Sciences, according to which practically the entire production lot buys of the Means for the next few months. However, it has created, for example, Germany, already supplies. The EU Commission is also negotiating with the manufacturer to secure sufficient quantities of the active ingredient.
Eobla drug helps Covid-19
The CDU-Europe politician Peter Liese stressed that a condition for the approval in Europe is that the manufacturer will deliver to Europe. A possible solution for the bottlenecks would be, that Gilead share his knowledge with other producers, and this leave against license fees produce. Also, so that Gilead could earn a lot of money, said Liese on Friday.
Remdesivir was originally developed for the treatment of Ebola, but showed a low effect. It is not yet approved in any country in the world fully as a drug. So far there is no vaccine against the novel Coronavirus, and also no reliable approved drug therapy.